Citation Impact
Citing Papers
Conflict of Interest in Medical Research, Education, and Practice
2009 Standout
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials
2001 Standout
Adrenergic α2C-Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice
1998 StandoutNobel
Survey on the pharmacodynamics of the new antipsychotic risperidone
1994
Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel‐group trial
1995
Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography
1993
Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone
1998 StandoutNobel
DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS
2002
Evoked gamma band synchronization and the liability for schizophrenia*1
2004
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
1995
Risperidone versus haloperidol: I. meta-analysis of efficacy and safety
1998
Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia
2004
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
2006
How to perform a meta-analysis with R: a practical tutorial
2019 Standout
Psychiatric diagnoses in 3275 suicides: a meta-analysis
2004 Standout
Risperidone Treatment of Children and Adolescents with Chronic Tic Disorders: A Preliminary Report
1995
Twelve-Month Use of Mental Health Services in the United States
2005 Standout
How to treat OCD in patients with Tourette syndrome
2003
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment
2002 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
The status of spectral EEG abnormality as a diagnostic test for schizophrenia
2007
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
2012
A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders
1998
Case Study: Risperidone in Children and Adolescents with Schizophrenia
1995
Phencyclidine in the Social Interaction Test: An Animal Model of Schizophrenia with Face and Predictive Validity
1999
Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence
2002
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
2005 Standout
Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: Antagonism by atypical antipsychotic drugs
1994
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia
2006
A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder
2001
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia
2002 Standout
Smoking and Mental Illness
2000 Standout
A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial
1997
Dose Response and Dose Equivalence of Antipsychotics
2004
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability
1995
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
2000 Standout
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
1996
A review of central 5-HT receptors and their function
1999 Standout
Haloperidol versus placebo for schizophrenia
2001
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
1999 Standout
Quetiapine in Patients With Schizophrenia
1997
Redundancy, disaggregation, and the integrity of medical research
1996
A Systematic Review of Mortality in Schizophrenia
2007 Standout
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
1999
Psychiatric Aspects of Impulsivity
2001 Standout
Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome
1998
Alzheimer's Disease
2004 Standout
The new and evolving pharmacotherapy of schizophrenia
2003
Schizophrenia and Nicotine Use: Report of a Pilot Smoking Cessation Program and Review of Neurobiological and Clinical Issues
1997
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
2007
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
2004
IN VITRO EFFECTS OF ANTIPSYCHOTICS ON HUMAN PLATELET ADHESION AND AGGREGATION AND PLASMA COAGULATION
2007 StandoutNobel
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
2008
Impact of covert duplicate publication on meta-analysis: a case study
1997 Standout
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
2003
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
2003 Standout
Bias in meta-analysis detected by a simple, graphical test
1997 Standout
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
2007 Standout
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia
1999
Industry sponsorship and research outcome
2012 Standout
Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications
2012
Imputation methods for missing outcome data in meta-analysis of clinical trials
2008
Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia
1997
Abnormal neural oscillations and synchrony in schizophrenia
2010 Standout
Risperidone versus typical antipsychotic medication for schizophrenia
2003
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration
2014 Standout
Pharmacological interventions for somatoform disorders in adults
2014 Standout
Towards More Effective Antipsychotic Treatment
1994
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
1999
How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study
2003 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia
2005
Optimal Haloperidol Dosage in First-Episode Psychosis
1999
Neuroleptic Dosing and Neuroleptic Plasma Levels in Schizophrenia: Determining the Optimal Regimen
1995
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
1999
Risperidone
1994
Pharmacotherapy of first-episode schizophrenia
1998
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
2008 Standout
Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders
2007
Haloperidol versus placebo for schizophrenia
2013
Risperidone versus placebo for schizophrenia
2016
Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses
2001 Standout
Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
1997 Standout
Dopamine Receptors: From Structure to Function
1998 Standout
Risperidone Dose-Dependently Increases Extracellular Concentrations of Serotonin in the Rat Frontal Cortex: Role of α2-Adrenoceptor Antagonism
1997
Industry sponsorship and research outcome
2017 Standout
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target
2003
The role of serotonin in the pathophysiology and treatment of schizophrenia
1997
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Adherence to antipsychotic medications.
1999
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials
1997
Hallucinogens
2004 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of A. Labelle being referenced
Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment
2001
A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients
1993